The stock of Entero Therapeutics Inc (NASDAQ: ENTO) has increased by 33.53% when compared to last closing price of $0.4. Despite this, the company has experienced a 32.52% gain in its stock price over the last five trading sessions. newsfilecorp.com reported 2025-06-13 that Calgary, Alberta–(Newsfile Corp. – June 13, 2025) – FluroTech Ltd. (TSXV: TEST.H) (“FluroTech” or the “Company”) is pleased to announce that effective June 12, 2025, Eric Corbett has been appointed to the board of directors.
Is It Worth Investing in Entero Therapeutics Inc (NASDAQ: ENTO) Right Now?
Company’s 36-month beta value is 0.78.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ENTO is 4.44M, and currently, short sellers hold a 6.45% ratio of that floaft. The average trading volume of ENTO on July 09, 2025 was 1.24M shares.
ENTO’s Market Performance
The stock of Entero Therapeutics Inc (ENTO) has seen a 32.52% increase in the past week, with a 7.74% rise in the past month, and a 4.15% gain in the past quarter. The volatility ratio for the week is 13.28%, and the volatility levels for the past 30 days are at 14.82% for ENTO. The simple moving average for the last 20 days is 11.60% for ENTO stock, with a simple moving average of 6.37% for the last 200 days.
ENTO Trading at 22.41% from the 50-Day Moving Average
After a stumble in the market that brought ENTO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.26% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ENTO starting from Romano Sarah, who sale 727 shares at the price of $0.64 back on Jan 06 ’25. After this action, Romano Sarah now owns 17,287 shares of Entero Therapeutics Inc, valued at $465 using the latest closing price.
Romano Sarah, the Chief Financial Officer of Entero Therapeutics Inc, sale 476 shares at $0.45 during a trade that took place back on Oct 09 ’24, which means that Romano Sarah is holding 18,014 shares at $212 based on the most recent closing price.
Stock Fundamentals for ENTO
The total capital return value is set at -0.13. Equity return is now at value -33.24, with -25.32 for asset returns.
Based on Entero Therapeutics Inc (ENTO), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -7.53. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -410.21.
Currently, EBITDA for the company is 15606.71 with net debt to EBITDA at -0.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.90.
Conclusion
In a nutshell, Entero Therapeutics Inc (ENTO) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
